SCHEMBL3020358

SCHEMBL3020358

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4Cl)CC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.61
USP2 O75604 2/20 0.61
RECQL P46063 1/20 0.61
HSD17B10 Q99714 1/20 0.61
SMN1; SMN2 Q16637 7/20 0.60
ALDH1A1 P00352 6/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MAPK1 P28482 7/20 0.59
LMNA P02545 7/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
POLB P06746 2/20 0.56
AR P10275 1/20 0.54
RAB9A P51151 3/20 0.53
NPC1 O15118 1/20 0.53
TDP1 Q9NUW8 2/20 0.52
TP53 P04637 3/20 0.49
HTT P42858 3/20 0.47
ALOX15 P16050 1/20 0.47
FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653752 0.96 MAPT (0.58) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3010542 0.93 MAPT (0.64) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3011236 0.91 MAPT (0.62) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3003209 0.90 POLB (0.58) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3010297 0.90 MAPT (0.77) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3008752 0.90 SMN1; SMN2 (0.57) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3649567 0.89 MAPT (0.61) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3013888 0.89 SMN1; SMN2 (0.64) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3003206 0.89 SMN1; SMN2 (0.66) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3009047 0.89 MAPT (0.57) MAPTUSP2RECQLHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.